Sucralose

What this is

Sucralose is one of the major high-intensity sweeteners used to replace sugar while keeping sweetness. FDA allows it as a general-purpose sweetener under GMP, and JECFA and EFSA have established ADIs of 0–15 and 15 mg/kg bw/day, respectively; FDA’s ADI is 5 mg/kg bw/day. In 2026 EFSA re-evaluated E955 and concluded current EU uses remain below the ADI and do not present a safety concern, while noting uncertainty for expanded fine-bakery uses and home high-temperature baking or frying where chlorinated degradation products could form. A 2023 in vitro study of sucralose-6-acetate reported genotoxic and intestinal-barrier signals, which keeps the concern from being “Low” here; regulators have not translated that into a broad ban. WHO’s 2023 non-sugar sweetener guideline is about weight-control and public-health policy, not a toxicological reassessment or replacement for JECFA/ADI limits.

Safety Review

The critical endpoints experts review in safety assessments. This is not a prediction of harm.

EFSA found no genotoxicity concern for sucralose at current EU uses, but could not confirm some expanded or high-temperature uses because chlorinated degradation products may form. The packet also cites a 2023 in vitro study of sucralose-6-acetate reporting genotoxic and intestinal-barrier signals; regulators have not translated that into a broad ban.